Active Clinical Trials

December 20, 2022

Re-Opened Trial: EA9152 for T-cell or B-cell Acute Lymphoblastic Leukemia

This study is investigating the safety and efficacy of venetoclax, a BCL-2 inhibitor, in combination with vincristine sulfate in the relapsed or refractory ALL population
December 20, 2022

Trial Spotlight: Robert Ferris on the EA3132 Trial for Patients with Head and Neck Cancer

This phase 2 study is examining whether the addition of cisplatin to PORT will provide a survival benefit to certain patients with stage 3/4 squamous cell carcinoma of the head and neck
October 13, 2022

Trial Spotlight: Yishai Ofran on the EA9181 Study for Acute Lymphoblastic Leukemia

This phase 3 study aims to explore whether treatment with a TKI plus blinatumomab may be superior to the usual treatment approach for acute lymphoblastic leukemia
August 16, 2022

NCI-MATCH precision medicine trial leads to FDA drug approval for BRAF V600E-mutated tumors

Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation
August 16, 2022

Trial Spotlight: Neha Vapiwala on the EA8191/INDICATE Study for Prostate Cancer

This phase III study is using PET/CT imaging to guide treatment for patients with post-prostatectomy biochemical recurrence
June 21, 2022

Now Enrolling: EA9213 for T-Cell Acute Lymphoblastic Leukemia

This single-arm phase II study aims to rid patients of residual disease following initial treatment
June 21, 2022

Trial Spotlight Video: The EA8192 Study Team Discusses Their Trial for High Grade Upper Tract Urothelial Cancer

This study seeks to determine if neoadjuvant treatment with durvalumab and chemotherapy improves patient outcomes over chemotherapy alone
April 15, 2022

Now Enrolling: ECOG-ACRIN Opens a New NCI-MATCH Treatment Arm for dMMR and LAG-3-Positive Cancers as it Continues to Locate Patients with BRAF Mutations

The ground-breaking NCI-MATCH precision medicine cancer trial continues to offer treatment opportunities for adult patients with relapsed, refractory cancers. Lead investigators Nilo Azad, MD, and April Salama, MD, discuss Arms Z1M and H.
April 15, 2022

NCI-MATCH: The Blueprint for Future Precision Medicine Trials

In an enormous undertaking, ECOG-ACRIN and the NCI have built the knowledge base and infrastructure for future precision medicine trials. The new Genomics Subcommittee is offering expertise moving forward.
April 15, 2022

Trial Spotlight: Nadine Tung on the EA1181/CompassHER2 pCR Trial for HER2-Positive Breast Cancer

This study aims to determine if it is safe to omit adjuvant chemotherapy after surgery for patients with pathologic complete response (pCR) after 12 weeks of pre-operative treatment
February 24, 2022

Now Enrolling: EA2205 for a Rare Form of Liver Cancer

ECOG-ACRIN is leading the first randomized trial evaluating treatment strategies for patients with combined hepatocellular carcinoma-cholangiocarcinoma
February 24, 2022

Trial Spotlight: Nataliya Uboha on the EA2183 Trial for Esophageal and Gastric Adenocarcinoma

This randomized phase III trial explores the addition of radiotherapy to the usual treatment (chemotherapy) in patients with esophagus and stomach cancer with limited spread